VTGN News and Press, VistaGen Therapeutics Inc. From 04/01/24

Key study underway in registration-directed PALISADE Phase 3 program for fasedienol in social anxiety disorder Social anxiety disorder affects over 25 million Americans Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to delive...

2024-03-20 21:01:28 ET Summary Vistagen Therapeutics has proprietary platform technologies for developing innovative drugs for mental health disorders. The company's pipeline includes candidates for social anxiety disorder, major depressive disorder, vasomotor symptoms, and more. ...

2024-03-17 03:07:49 ET Summary VistaGen Therapeutics is developing CNS drugs for anxiety, depression, and other disorders, with Fasedienol in phase 3 clinical trials. Fasedienol has advantages as a non-systemic, low-abuse anxiolytic and is seeking Breakthrough Therapy Designation....

Vistagen Therapeutics (NASDAQ: VTGN) , a biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, will be featured at the upcoming Stifel 2024 Virtual CNS Days. The two-day online event is scheduled f...

Vistagen (Nasdaq: VTGN), a biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced that company management will present and host one-on-one meetings during the Stifel 2024 Virtual CNS...

Vistagen (NASDAQ: VTGN) , a biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced that company management will present and host one-on-one meetings at the TD Cowen 44th Annual Healt...

Vistagen (Nasdaq: VTGN), a biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced that company management will present and host one-on-one meetings at the TD Cowen 44 th Annual H...

2024-02-19 12:24:46 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Investing in high-potential biotech stocks should catapult your portfolio to new heights. Picture this: a global biotech market valued at a whopping $1.55 trillion in 2023 is set to catapul...

Vistagen Therapeutics (NASDAQ: VTGN) , a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver first-in-class therapies for psychiatric and neurological disorders, is reporting its Q3 2024 financial numbers as well as providing an update on the company. Notable numbers ...

2024-02-13 18:34:02 ET Vistagen Therapeutics, Inc. (VTGN) Q3 2024 Earnings Conference Call February 13, 2024, 05:00 PM ET Company Participants Mark McPartland - Senior Vice President, Investor Relations Shawn Singh - Chief Executive Officer Cindy Anderson - Chief...